Genomic sequencing Assessment of 733 HER2-amplified Principal and metastatic breast tumours discovered considerable enrichment of mutations that activate RAS–MAPK signalling in advanced tumours addressed with prior anti-HER2 therapies121. These mutations, which includes NF1 and HER2 activating mutations, add to resistance to tucatinib and neratinib. A critical consideration regarding ... https://www.directivepublications.org/journal-of-clinical-breast-cancer/